TCRT — Alaunos Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.15m
- $3.06m
- $0.01m
Annual cashflow statement for Alaunos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -80 | -78.8 | -37.7 | -35.1 | -4.68 |
| Depreciation | |||||
| Non-Cash Items | 6.83 | 11.9 | 4.38 | 8.65 | 0.435 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 15 | 2.79 | 1.36 | -5.97 | -0.729 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -57 | -61.5 | -29.2 | -30.1 | -4.97 |
| Capital Expenditures | -9.78 | -3.32 | -0.216 | -0.197 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | 0.023 | 1.54 | 0 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -9.78 | -3.32 | -0.193 | 1.35 | 0 |
| Financing Cash Flow Items | — | -0.26 | 0 | -0.125 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 102 | 25.8 | 6.37 | -18.1 | 0 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 35.3 | -39 | -23.1 | -46.9 | -4.97 |